ZENSUN ENT (00185) has released its interim results for the six months ended June 30, 2026, revealing a substantial narrowing of its net loss year-on-year.

The group recorded revenue of approximately RMB 357 million for the period, marking a steep decline of about 86.4% compared to the same period last year.

Despite the sharp drop in top-line performance, the company's loss attributable to shareholders came in at roughly RMB 301 million, a reduction of approximately 40.0% from the prior corresponding period.

Basic loss per share stood at RMB 15.7 cents, reflecting the improved bottom-line figure against the backdrop of reduced operational scale.